SCHEMBL3145638

SCHEMBL3145638

N#Cc1ccc(C#CCN2CCN(c3nc(-c4ccc(Cl)cc4)cs3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MAPT P10636 9/20 0.50
LMNA P02545 3/20 0.50
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
EGFR P00533 2/20 0.47
KDR P35968 2/20 0.47
ERBB4 Q15303 2/20 0.47
ERBB2 P04626 1/20 0.47
IGF1R P08069 1/20 0.47
ALDH1A1 P00352 2/20 0.46
HTT P42858 2/20 0.46
HSD17B10 Q99714 1/20 0.46
CASP1 P29466 1/20 0.45
AR P10275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3156289 0.81 SMN1; SMN2 (0.58) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3145642 0.80 MAPT (0.59) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3151277 0.79 CYP1A2 (0.54) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL2708485 0.77 AR (0.54) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3160607 0.76 CYP1A2 (0.54) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL14046467 0.76 CHEK1 (0.57) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3146632 0.75 RAB9A (0.53) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL29157423 0.74 SMN1; SMN2 (0.70) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL17014750 0.74 AR (0.69) MAPK1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL3148620 0.73 LMNA (0.44) NPC1RAB9ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP claimed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US claimed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP disclosed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 MAPK1 1290/4885SMN1; SMN2 937/4885NPC1 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.